TrialThe Lancet. Oncology2020

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.

Brian I Rini et al.PubMed ↗Publisher ↗

No numbers read from the abstract.